Macquarie Group LTD Halozyme Therapeutics, Inc. Transaction History

Macquarie Group LTD

$79.1 Billion
Q2 2025

A detailed history of Macquarie Group LTD transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Macquarie Group LTD holds 2,083,392 shares of HALO stock, worth $134 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares

2,083,392

Previous 2,674,273 22.1%

Holding current value

$134 Million

Previous $171 Million 36.49%

% of portfolio

0.14%

Previous 0.22%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$47.91 - $70.14 $28.3 Million - $41.4 Million	-590,881 Reduced 22.1%	2,083,392 $108 Million
Q1 2025 May 15, 2025	SELL	$47.74 - $65.16 $11 Million - $15.1 Million	-231,212 Reduced 7.96%	2,674,273 $171 Million
Q4 2024 Feb 14, 2025	SELL	$42.57 - $61.09 $4.48 Million - $6.44 Million	-105,340 Reduced 3.5%	2,905,485 $139 Million
Q3 2024 Nov 14, 2024	SELL	$51.3 - $64.42 $3.42 Million - $4.3 Million	-66,702 Reduced 2.17%	3,010,825 $172 Million
Q2 2024 Aug 09, 2024	BUY	$37.81 - $52.4 $3.27 Million - $4.53 Million	86,402 Added 2.89%	3,077,527 $161 Million
Q1 2024 May 14, 2024	SELL	$33.68 - $41.95 $9.82 Million - $12.2 Million	-291,515 Reduced 8.88%	2,991,125 $122 Million
Q4 2023 Feb 14, 2024	SELL	$33.32 - $42.1 $5.38 Million - $6.8 Million	-161,550 Reduced 4.69%	3,282,640 $121 Million
Q3 2023 Nov 14, 2023	BUY	$36.46 - $44.03 $4.92 Million - $5.94 Million	134,835 Added 4.07%	3,444,190 $132 Million
Q2 2023 Aug 14, 2023	BUY	$30.28 - $38.74 $3.3 Million - $4.22 Million	108,874 Added 3.4%	3,309,355 $119 Million
Q1 2023 May 15, 2023	BUY	$32.86 - $55.7 $19.6 Million - $33.2 Million	595,220 Added 22.85%	3,200,481 $122 Million
Q4 2022 Feb 21, 2023	BUY	$40.06 - $59.44 $2.01 Million - $2.99 Million	50,294 Added 1.97%	2,605,261 $148 Million
Q3 2022 Nov 14, 2022	BUY	$38.53 - $51.78 $1.33 Million - $1.78 Million	34,436 Added 1.37%	2,554,967 $101 Million
Q2 2022 Aug 15, 2022	BUY	$37.35 - $48.3 $1.71 Million - $2.22 Million	45,885 Added 1.85%	2,520,531 $111 Million
Q1 2022 May 16, 2022	SELL	$31.97 - $41.06 $19.1 Million - $24.6 Million	-598,310 Reduced 19.47%	2,474,646 $98.7 Million
Q4 2021 Feb 11, 2022	BUY	$31.82 - $40.75 $2.57 Million - $3.3 Million	80,889 Added 2.7%	3,072,956 $124 Million
Q3 2021 Nov 12, 2021	BUY	$38.47 - $46.42 $1.93 Million - $2.33 Million	50,129 Added 1.7%	2,992,067 $122 Million
Q2 2021 Aug 13, 2021	BUY	$38.84 - $51.31 $28.4 Million - $37.6 Million	731,878 Added 33.12%	2,941,938 $134 Million
Q1 2021 May 14, 2021	SELL	$39.51 - $51.45 $4.27 Million - $5.56 Million	-107,992 Reduced 4.66%	2,210,060 $92.1 Million
Q4 2020 Feb 16, 2021	BUY	$25.81 - $43.62 $4.43 Million - $7.48 Million	171,548 Added 7.99%	2,318,052 $99 Million
Q3 2020 Nov 13, 2020	BUY	$25.74 - $29.63 $49.2 Million - $56.6 Million	1,910,555 Added 809.73%	2,146,504 $56.4 Million
Q2 2020 Aug 11, 2020	BUY	$16.25 - $26.81 $22,506 - $37,131	1,385 Added 0.59%	235,949 $6.33 Million
Q1 2020 May 15, 2020	BUY	$13.9 - $21.83 $63,439 - $99,632	4,564 Added 1.98%	234,564 $4.22 Million
Q2 2019 Aug 14, 2019	SELL	$14.75 - $17.26 $2.51 Million - $2.93 Million	-170,000 Reduced 42.5%	230,000 $3.95 Million
Q1 2019 May 15, 2019	SELL	$13.94 - $17.58 $1.39 Million - $1.76 Million	-100,000 Reduced 20.0%	400,000 $6.44 Million
Q1 2018 May 11, 2018	SELL	$17.06 - $21.2 $69,946 - $86,920	-4,100 Reduced 0.81%	500,000 $9.8 Million
Q4 2017 Feb 15, 2018	BUY	$16.75 - $20.8 $68,675 - $85,280	4,100 Added 0.82%	504,100 $10.2 Million
Q3 2017 Nov 08, 2017	BUY	$11.76 - $17.4 $5.88 Million - $8.7 Million	500,000	500,000 $8.69 Million

Others Institutions Holding HALO

# of Institutions

600

Shares Held

127M

Call Options Held

408K

Put Options Held

388K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $8.95B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.

Account

Macquarie Group LTD Halozyme Therapeutics, Inc. Transaction History